AIM: To evaluate the potential prognostic value of GNAS1 T393C polymorphism in advanced non-small cell lung cancer. METHODS: We extracted genomic DNA from the peripheral blood leucocytes of 94 patients with advanced non-small cell lung cancer. Quantitative real-time polymerase chain reaction was used to determine the allelic discrimination. The correlation between genotype and overall survival was evaluated using the multivariate analysis and Kaplan-Meier approach. RESULTS: Thirty-eight out of 94 (40%) patients displayed a TT genotype, 29 out of 94 (31%) a CT genotype and 27 out of 94 (29%) a CC genotype. The median survival of TT (25 mo) genotype carriers was longer than CT (12 mo) or CC (8 mo) genotype carriers. The favorable TT genotype predicted better overall survival (OS) (2-year OS: 48%; P =0.01) compared with CT (2-year OS: 18%) or CC (2-year OS: 15%) genotype. However, dichotomization between C-genotypes (CC + CT) and T-genotypes (TT) revealed significantly lower survival rates (2-year OS: 16%; P = 0.01) for C allele carriers. CONCLUSION: Our data provided strong evidence that the GNAS1 T393C genetic polymorphism influenced the prognosis in advanced non-small lung cancer with a worse outcome for C allele carriers.
AIM: To evaluate the potential prognostic value of GNAS1T393C polymorphism in advanced non-small cell lung cancer. METHODS: We extracted genomic DNA from the peripheral blood leucocytes of 94 patients with advanced non-small cell lung cancer. Quantitative real-time polymerase chain reaction was used to determine the allelic discrimination. The correlation between genotype and overall survival was evaluated using the multivariate analysis and Kaplan-Meier approach. RESULTS: Thirty-eight out of 94 (40%) patients displayed a TT genotype, 29 out of 94 (31%) a CT genotype and 27 out of 94 (29%) a CC genotype. The median survival of TT (25 mo) genotype carriers was longer than CT (12 mo) or CC (8 mo) genotype carriers. The favorable TT genotype predicted better overall survival (OS) (2-year OS: 48%; P =0.01) compared with CT (2-year OS: 18%) or CC (2-year OS: 15%) genotype. However, dichotomization between C-genotypes (CC + CT) and T-genotypes (TT) revealed significantly lower survival rates (2-year OS: 16%; P = 0.01) for C allele carriers. CONCLUSION: Our data provided strong evidence that the GNAS1T393C genetic polymorphism influenced the prognosis in advanced non-small lung cancer with a worse outcome for C allele carriers.
Authors: Ulrich H Frey; Andreas Eisenhardt; Gerd Lümmen; Herbert Rübben; Karl-Heinz Jöckel; Kurt W Schmid; Winfried Siffert Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-04 Impact factor: 4.254
Authors: Klaus J Schmitz; Hauke Lang; Ulrich H Frey; Georgios C Sotiropoulos; Jeremias Wohlschlaeger; Henning Reis; Atsushi Takeda; Winfried Siffert; Kurt W Schmid; Hideo A Baba Journal: Neoplasia Date: 2007-02 Impact factor: 5.715
Authors: Ulrich H Frey; Hakan Alakus; Jeremias Wohlschlaeger; Klaus J Schmitz; Günther Winde; Hans G van Calker; Karl-Heinz Jöckel; Winfried Siffert; Kurt W Schmid Journal: Clin Cancer Res Date: 2005-07-15 Impact factor: 12.531
Authors: Michael T Collins; Nicholas J Sarlis; Maria J Merino; Jason Monroe; Susan E Crawford; Jonathan A Krakoff; Lori C Guthrie; Sandra Bonat; Pamela G Robey; Andrew Shenker Journal: J Clin Endocrinol Metab Date: 2003-09 Impact factor: 5.958
Authors: Goetz F Lehnerdt; Peter Franz; Anwar Zaqoul; Klaus J Schmitz; Sara Grehl; Stephan Lang; Kurt W Schmid; Winfried Siffert; Klaus Jahnke; Ulrich H Frey Journal: Clin Cancer Res Date: 2008-03-15 Impact factor: 12.531
Authors: Jubao Duan; Mark S Wainwright; Josep M Comeron; Naruya Saitou; Alan R Sanders; Joel Gelernter; Pablo V Gejman Journal: Hum Mol Genet Date: 2003-02-01 Impact factor: 6.150